secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001193125-24-132559
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal posts Q1 net loss of ~$147.5M as Rezdiffra launch ramps up
-------------------------------------------------------------------

- Rezdiffra received FDA accelerated approval on March 14, 2024; first shipments to patients began in April.
- No Q1 revenue; operating expenses of $152.0M (up 94% YoY) due to commercial preparation and headcount.
- Cash, cash equivalents and marketable securities of $1.1B after $690M gross proceeds from public offering.
- Appointed Mardi C. Dier as CFO on February 28, 2024.
- European MAA for resmetirom validated and under EMA review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524132559/0001193125-24-132559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524132559/d828444d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-132559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer